Gidding SS, Duffy CE, Pajcic S, Berdusis K, Shulman ST Usefulness of echocardiographic evidence of pericardial effusion and mitral regurgitation during the acute stage in predicting development of coronary arterial aneurysms in the late stage of Kawasaki disease. Am J Cardiol. 1987 Jul 1;60(1):76-9.
Gidding SS, Shulman ST, Ilbawi M, Crussi F, Duffy CE Mucocutaneous lymph node syndrome (Kawasaki disease): delayed aortic and mitral insufficiency secondary to active valvulitis. J Am Coll Cardiol. 1986 Apr;7(4):894-7.
Hicks RV, and Melish ME: Kawasaki Syndrome In: Michael L. Miller (editor) The Pediatric Clinics of North American (Pediatric Rheumatology), pp. 1151-1175. W.B. Saunders Co., October 1986.
Leung DY, Burns JC, Newburger JW, Geha RS Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987 Feb;79(2):468-72.
Melish ME, and Hicks RV Kawasaki Syndrome. In: John D. Nelson (editor) Current Therapy in Pediatric Infectious Disease, pp. 106-162. The C.V. Mosby Co., 1986.
Rowley AH, Shulman ST Kawasaki disease: new etiologic clues and advances in therapy. Pediatr Dermatol. 1987 Aug;4(2):134-5.
Rowley AH, Shulman ST The search for the etiology of Kawasaki disease. Pediatr Infect Dis J. 1987 Jun;6(6):506-8. Review.
Rowley AH, Shulman ST What is the status of intravenous gamma-globulin for Kawasaki syndrome in the United States and Canada? Pediatr Infect Dis J. 1988 Jul;7(7):463-6. Review.
Shulman ST, Rowley AH Does Kawasaki disease have a retroviral aetiology? Lancet. 1986 Sep 6;2(8506):545-6.
Takahashi M, Mason W, Lewis AB Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation. 1987 Feb;75(2):387-94.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
